📊 BBNX Key Takeaways
Is Beta Bionics, Inc. (BBNX) a Good Investment?
Beta Bionics demonstrates strong top-line revenue growth (+53.9% YoY) and healthy gross margins (59.5%), indicating a viable product offering in the medical device sector. However, the company is deeply unprofitable with severe operating losses (-$24.3M) and negative free cash flow (-$25.2M), while net losses worsened 33.7% YoY despite revenue growth. At current burn rate and $30.2M cash position, the company faces a critical need to achieve profitability within 12-15 months or require significant capital infusion.
Beta Bionics is showing strong top-line momentum, with revenue up 53.9% year over year and a solid 55.4% gross margin, indicating meaningful commercial traction and a viable product economics base. However, the business remains deeply unprofitable, with operating and free cash flow losses still very large relative to revenue, so the fundamental story depends on whether growth can translate into materially improved operating leverage.
Why Buy Beta Bionics, Inc. Stock? BBNX Key Strengths
- Strong revenue growth momentum at 53.9% YoY indicates market demand
- Healthy gross margin of 59.5% demonstrates strong product pricing power and unit economics
- Excellent liquidity position with current ratio of 10.69x and minimal debt provides runway for operations
- Revenue growth is strong at 53.9% year over year, indicating expanding adoption
- Gross margin of 55.4% suggests the core product economics are reasonably attractive
- Balance sheet is strong with high liquidity, substantial equity capital, and no meaningful debt burden
BBNX Stock Risks: Beta Bionics, Inc. Investment Risks
- Severe operating losses (-$24.3M) despite growing revenue indicates runaway operating expenses and poor cost control
- Negative free cash flow of -$25.2M with only $30.2M cash creates sustainability concerns within 12-15 months
- Deteriorating bottom-line performance (net income down 33.7% YoY) despite top-line growth suggests scaling challenges and inability to leverage revenue growth into profitability
- Operating margin of -71.5% shows the company is still far from sustainable profitability
- Free cash flow of -$56.22M and negative operating cash flow indicate continued cash burn
- Returns on equity and assets are deeply negative, suggesting current growth is not yet generating efficient earnings power
Key Metrics to Watch
- Operating margin trajectory and path to breakeven
- Operating cash flow trends and monthly burn rate
- Revenue per unit and gross profit growth relative to headcount expense growth
- Operating loss and free cash flow burn relative to revenue growth
- Gross margin stability and improvement in operating margin as scale increases
Beta Bionics, Inc. (BBNX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.69x current ratio provides a solid financial cushion.
BBNX Profit Margin, ROE & Profitability Analysis
BBNX vs Healthcare Sector: How Beta Bionics, Inc. Compares
How Beta Bionics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Beta Bionics, Inc. Stock Overvalued? BBNX Valuation Analysis 2026
Based on fundamental analysis, Beta Bionics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Beta Bionics, Inc. Balance Sheet: BBNX Debt, Cash & Liquidity
BBNX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Beta Bionics, Inc.'s revenue has grown significantly by 54% over the 5-year period, indicating strong business expansion. The most recent EPS of $-8.60 indicates the company is currently unprofitable.
BBNX Revenue Growth, EPS Growth & YoY Performance
BBNX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $17.6M | -$21.9M | $-0.49 |
| Q3 2025 | $16.7M | -$9.7M | $-0.33 |
| Q2 2025 | $15.0M | -$14.5M | $-0.39 |
| Q1 2025 | $12.9M | -$12.4M | $-0.93 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Beta Bionics, Inc. Dividends, Buybacks & Capital Allocation
BBNX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Beta Bionics, Inc. (CIK: 0001674632)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BBNX
What is the AI rating for BBNX?
Beta Bionics, Inc. (BBNX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BBNX's key strengths?
Claude: Strong revenue growth momentum at 53.9% YoY indicates market demand. Healthy gross margin of 59.5% demonstrates strong product pricing power and unit economics. ChatGPT: Revenue growth is strong at 53.9% year over year, indicating expanding adoption. Gross margin of 55.4% suggests the core product economics are reasonably attractive.
What are the risks of investing in BBNX?
Claude: Severe operating losses (-$24.3M) despite growing revenue indicates runaway operating expenses and poor cost control. Negative free cash flow of -$25.2M with only $30.2M cash creates sustainability concerns within 12-15 months. ChatGPT: Operating margin of -71.5% shows the company is still far from sustainable profitability. Free cash flow of -$56.22M and negative operating cash flow indicate continued cash burn.
What is BBNX's revenue and growth?
Beta Bionics, Inc. reported revenue of $27.6M.
Does BBNX pay dividends?
Beta Bionics, Inc. does not currently pay dividends.
Where can I find BBNX SEC filings?
Official SEC filings for Beta Bionics, Inc. (CIK: 0001674632) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BBNX's EPS?
Beta Bionics, Inc. has a diluted EPS of $-0.49.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BBNX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Beta Bionics, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BBNX stock overvalued or undervalued?
Valuation metrics for BBNX: ROE of -8.1% (sector avg: 15%), net margin of -79.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BBNX stock in 2026?
Our dual AI analysis gives Beta Bionics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BBNX's free cash flow?
Beta Bionics, Inc.'s operating cash flow is $-23.8M, with capital expenditures of $1.4M. FCF margin is -91.3%.
How does BBNX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -79.3% (avg: 12%), ROE -8.1% (avg: 15%), current ratio 10.69 (avg: 2).